BioCardia, Inc. (BCDA)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
BCDA achieves PMDA alignment for US data supporting Japanese market clearance
# 🧾 What This Document Is 📰 This filing is a Form 8-K, which is a report used to announce major, unscheduled corporate events that shareholders and the public should know about right away. Instead of detailing routine financial updates, this document is primarily a press release outlining a major
BioCardia, Inc. — 8-K Filing
# 🧾 What This Document Is This is an **8-K filing**, which is a current report companies use to announce major events to shareholders. Think of it as a breaking news alert to the market. BioCardia is telling investors it has formally asked the FDA for a meeting to discuss a faster path to getting i
SEC filings
All filings →Insider trades
All insider trades →BioCardia, Inc. has no reported insider trades in the last 90 days.